Wednesday, February 21, 2024
More
    HomeWorldVeteran Psychedelic Therapy Gets Cautious Support at First House Hearing of Its...

    Veteran Psychedelic Therapy Gets Cautious Support at First House Hearing of Its Kind Since 1960s

    Veteran Psychedelic Therapy Gets Cautious Support at First House Hearing of Its Kind Since 1960s

    Lawmakers and Veterans Affairs officials on Tuesday touted the potential for psychedelic drugs to treat mental health conditions and prevent veteran suicide, but they said additional research and FDA-approval is needed before the therapies could be available.

    In one of the first hearings in Congress on psychedelics since 1966, when Dr. Timothy Leary testified on the therapeutic potential for LSD, a House Veterans Affairs panel drilled VA physicians and advocates on psychiatric treatments that use MDMA, known recreationally as molly or ecstasy, and psilocybin, or magic mushrooms.

    Researchers for the Multidisciplinary Association for Psychedelic Studies, or MAPS, have studied the safety and effectiveness of MDMA-assisted psychotherapy for post-traumatic stress disorder since 2004. The protocol calls for patients taking MDMA in the presence of a therapist, who then leads them through counseling. The treatment involves three eight-hour sessions.

    Read Next: Coast Guard Helicopter Crashes, 2 Seriously Injured, in Alaska Search-and-Rescue Mission

    In September, scientists published results of a recent clinical trial of MDMA-assisted therapy that showed 87% of patients had significant improvement in symptoms four months after treatment, and by the study's end, 71% no longer met the diagnostic criteria for post-traumatic stress disorder.

    The treatment, designated a “breakthrough therapy” by the Food and Drug Administration in…

    Continue Reading This Article At Military.com

    Stay Connected

    34,572FansLike
    4,123FollowersFollow
    1,739FollowersFollow

    Latest articles

    AlphaDog Hosting Ad

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here
    Captcha verification failed!
    CAPTCHA user score failed. Please contact us!